The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

Not yet recruiting

• Conditions: Glioblastoma; Glioblastoma Multiforme (GBM)

• Registration Number: NCT07052877
• Lead Sponsor: Royal North Shore Hospital

Brief Summary

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-06-23
• Status Verified: 2025-07
• Study Start: 2025-07-01
• Study First Submitted QC: 2025-07-01
• Study First Posted: 2025-07-07
• Last Update Submitted: 2025-07-08
• Last Update Posted: 2025-07-11
• Primary Completion: 2027-07
• Study Completion: 2027-07-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• > 18 year of age
• ECOG 0-2
• Able to provide informed consent for the study
• Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
• Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
• For bevacizumab treatment as per treating physician
• Able to comply with trial requirements

Exclusion Criteria

• No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
• Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
• Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
• Does not fulfill PBS requirements for bevacizumab
• Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.	Prior to first administration of bevacizumab to 6 weeks after.

Trial Locations

Locations (1)

Royal North Shore Hospital; 🇦🇺 Saint Leonards, New South Wales, Australia